Last reviewed · How we verify

Paion UK Ltd. — Portfolio Competitive Intelligence Brief

Paion UK Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Morphine 6-glucuronide Morphine 6-glucuronide phase 3 Opioid receptor agonist Mu-opioid receptor (μ-OR) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of Pennsylvania · 2 shared drug classes
  2. Albert Einstein Healthcare Network · 1 shared drug class
  3. Centro Medico Nacional La Raza, IMSS · 1 shared drug class
  4. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
  5. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  6. Bausch Health · 1 shared drug class
  7. Assaf-Harofeh Medical Center · 1 shared drug class
  8. Ajenat Pharms · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Paion UK Ltd.:

Cite this brief

Drug Landscape (2026). Paion UK Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/paion-uk-ltd. Accessed 2026-05-16.

Related